We observed exclusively hyperactivated mTOR signaling in lung cancer patient samples with KRAS-mutations but not in those carrying wild-type KRAS. Combined clinically approved mTOR inhibitor and chemotherapy showed a strong synergism in inhibiting proliferation of cancer cells harboring KRAS-mutation specifically. This evidence concerns the gene KRAS and lung carcinoma.